Drug intelligence / Profile preview

RO5271983

Development stage: Phase 1
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

RO5271983 is a small molecule drug developed by F. Hoffmann-La Roche (Roche) as an antagonist of the prostaglandin D2 receptor 2 (CRTH2). Its mechanism of action involves blocking CRTH2, which is implicated in inflammatory and allergic responses. The compound was evaluated in phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. There are no approved indications or known adverse events reported for this drug[1][2][3].

Targets

PTGDR2 (Prostaglandin D2 receptor 2)

Beyond the preview

Go deeper on RO5271983.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO5271983.

Explore the full profile